Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 13
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Folate- and aCD47-functionalized lipid nanoparticles efficiently deliver mRNA and remodel pancreatic tumor microenvironment

  • Parés, Marta
  • Pallaruelo-Santamaría, Víctor
  • Fillat, Cristina
  • Martínez-Latorre, Javier|||0000-0001-5421-5371
  • Candela-Noguera, Vicente
  • Soriano-Teruel, Paula
  • García-Fernández, Alba|||0000-0002-8416-1674
  • Aznar, Elena|||0000-0003-0361-3876
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Abstract: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive and treatment-resistant malignancies, with limited efficacy to conventional treatments such as surgical resection or chemotherapy. This clinical scenario underscores the need for novel therapeutic strategies. The development of multifunctional platforms capable of targeting tumors through multiple mechanisms offers an innovative strategy to overcome this challenge. Lipid nanoparticles (LNPs) offer a versatile platform capable of efficiently delivering genetic material. Moreover, through surface functionalization it is feasible to improve LNP performance optimizing therapeutic outcomes in a single formulation. Here, we explored a dual functionalization strategy of the LNP for tumor targeting and tumor remodeling to improve treatment efficacy. LNPs were designed for delivering reporter DNA plasmid or mRNA into the PDAC cellular models Capan-2 and PANC-1. The DNA plasmid contains a pancreatic cancer-specific chimeric promoter for transcriptional specificity to PDAC cells. Besides, LNPs were functionalized with folate and an anti-CD47 antibody to both target the folate receptor in PDAC cells and block CD47-mediated immune evasion. Both pDNA and mRNA LNPs targeted PDAC cells in a dose-dependent manner, with mRNA-LNPs demonstrating more efficient transfection. Notably, LNPs functionalized with the anti-CD47 antibody increased phagocytosis in vitro, and promoted an inflammatory phenotype of M1-like macrophages in mouse Capan-2 xenografts. This combinatorial design of the formulated LNP represents an innovative therapeutic strategy and opens future perspectives in the search for effective treatments for PDAC. Keywords: Lipid nanoparticles; Immunotherapy; ACD47; Folate; Macrophages; Pancreatic cancer, This research was supported by European Union s Horizon 2020 research and innovation programme under grant agreement No 899708 (ULISES). The work has also received funding from projects PID2020- 119692RB-C22, PID2023-146637OB-C22, PID2021-128141OBC22, PID2021-126304OB-C41 and PID2024-155683OB-C41 funded by MCIN-Ministerio de Ciencia e Innovacion ¿ and by the European Regional Development Fund A way of doing Europe. This study was also supported by the ERC Advanced Grant Edison (101052997), the Generalitat Valenciana (CIPROM/2021/007) and CIBER (CB06/01/2012) and (RD21/0017/0012) Instituto de Salud Carlos III, the Generalitat de Catalunya (SGR21/01169). The research leading to these results has also received funding from la Caixa Foundation under agreement LCF/PR/ SP23/52950009. The Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Research Council. Neither the European Union nor the granting authority can be held responsible for them. J.M-L. is grateful to the Spanish MECD for his FPU grant (FPU19/06219). PM.S-T. is grateful to the Generalitat Valenciana for a postdoctoral Investigo contract (INVEST/2023/443). We also acknowledge the support of CERCA Programme/Generalitat de Catalunya.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Electrocardiographic Imaging: A New Tool to Ensure Cardiac Resynchronization During Left Bundle Branch Pacing Implant

  • Pujol-López, Margarida
  • Regany-Closa, Mariona
  • Pellicer-Sendra, Berta
  • Martínez-Pérez, Marta
  • Molero, Ruben
  • Graterol, Freddy R.
  • Guasch, Eduard
  • Tolosana, José M.
  • Mont, Lluís
  • Guillem Sánchez, María Salud|||0000-0001-5660-3693
[EN] Left bundle branch pacing (LBBP) has emerged as an alternative to biventricular pacing for cardiac resynchronization therapy (CRT). The objective is to pursue and ensure resynchronization. However, LBBP capture could fail to achieve adequate resynchronization in some patients, in whom biventricular pacing should be attempted., M.P.-L. is currently funded (2023-2025) through a Rio Hortega contract CM22/00107 [Instituto de Salud Carlos III (ISCIII); Fondo Social Europeo(FSE)]. J.M.T. and M.P.-L. received funding for Project in Conduction System Pacing (FIS PI21/00615) from Instituto de Salud Carlos III (Madrid, Spain). L.M.was funded by a 2021 Support for Research Groups grant from the Catalan government (2021_SGR_01350, SGR21/GENCAT), Catalonia, Spain. J.M.T., L.M.,M.R.-C., M.P.-L., and M.S.G. were funded by "La Marato de TV3 Fundacio", project: 202335 10, Barcelona, Catalonia, Spain. The authors thank the CERCAProgramme/Generalitat de Catalunya for the support to Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS). M.S.G and M.M.-P were funded byEIT Health and H2020 Grant n & zcaron; 230129. R.M. was funded by PTQ2023-012972 and CPP2021-008562 (CARE-ECGI). B.P.-S and M.S.G were supported byPLEC2021-007614 funded by MCIN/AEI/10.13039/501100011033 and EU NextGenerationEU/PRTR. This publication is part of the CPP2021-008562 CARE-ECGIproject -Cardiac resynchronization therapy based on electrocardiographic imaging-, funded by MCIN/AEI/10.13039/501100011033 and by the European Union"NextGenerationEU/PRTR".
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Tesis doctoral (DoctoralThesis)

Remodeling the tumor immune microenvironment with lipid nanoparticles

  • Martínez-Latorre, Javier|||0000-0001-5421-5371
[ES] Esta tesis doctoral, titulada "Remodelación del microambiente inmunitario tumoral con nanopartículas lipídicas", explora el desarrollo de nuevas estrategias inmunoterapéuticas contra el cáncer, tanto a nivel terapéutico como de métodos de administración. En concreto, el trabajo investiga enfoques alternativos y relativamente poco explorados, como las inmunoterapias basadas en macrófagos y la inmunoterapia mediada por antígenos exógenos, que tratan de superar las principales limitaciones de las modalidades inmunoterapéuticas actuales. Paralelamente, la tesis evalúa las nanopartículas lipídicas (LNP) como sistemas de administración de genes no virales para la inmunoterapia. El primer capítulo experimental describe el desarrollo de una novedosa plataforma LNP para la inmunoterapia basada en macrófagos. Las LNP cargadas con ADN plasmídico o ARNm de luciferasa se funcionalizaron con ácido fólico (FA) para dirigirse a las células cancerosas pancreáticas que expresan el receptor de folato y con un anticuerpo anti-CD47 (aCD47) para bloquear la evasión inmunitaria mediada por CD47. Los resultados demuestran una transfección eficaz de las células de cáncer de páncreas, con las LNP cargadas con ARNm superando a las formulaciones basadas en plásmidos. Además, la funcionalización con FA mejoró la captación dirigida de LNP in vitro y la funcionalización con aCD47 restauró la fagocitosis de las células tumorales por los macrófagos in vitro. Los experimentos in vivo en modelos de xenoinjertos Capan-2 de ratón con LNP-ARNm-FA-aCD47 demostraron la expresión in vivo de luciferasa y promovieron un cambio hacia un fenotipo de macrófagos proinflamatorio M1 dentro del microambiente tumoral. En conjunto, estos resultados presentan una plataforma LNP optimizada, capaz de inmunomodular los macrófagos asociados a tumores. El segundo capítulo experimental presenta una novedosa inmunoterapia mediada por antígenos exógenos basada en el epítopo alpha-Gal (galactosa-alpha-1,3-galactosa). El epítopo alpha-Gal es altamente inmunogénico en humanos y provoca fuertes respuestas debido a anticuerpos preexistentes. Se desarrollaron LNP que codifican el ARNm de la alpha-1,3-galactosiltransferasa (alpha-GT) para permitir la biosíntesis endógena de alpha-Gal en la superficie de las células tumorales. El tratamiento con estas LNP indujo con éxito la expresión de alpha-Gal en líneas celulares cancerosas murinas y humanas y promovió el reclutamiento de anticuerpos anti-alpha-Gal humanos naturales hacia las células tumorales. Estos resultados identifican a la LNP alpha como una plataforma inmunoterapéutica prometedora que aprovecha la inmunidad humoral preexistente. El tercer capítulo experimental describe una novedosa inmunoterapia mediada por antígenos exógenos basada en la proteína hemaglutinina (H) del virus del sarampión. La proteína H es un antígeno altamente inmunogénico en humanos debido a la vacunación generalizada contra el virus del sarampión. Se formularon LNP que codifican la proteína H y se demostró que transfectan eficazmente tanto cultivos celulares cancerosos bidimensionales como esferoides tumorales tridimensionales. Además, la administración in vivo de LNP H en ratones vacunados contra el sarampión con tumores de melanoma B16-BL6 dio lugar a una disminución significativa del crecimiento tumoral. Este efecto terapéutico está asociado con una fuerte infiltración intratumoral de linfocitos T citotóxicos CD8+, un cambio en la proporción de células T CD8/CD4 y la producción ex vivo de citocinas proinflamatorias tras la reactivación del antígeno, características distintivas de una potente respuesta inmunitaria mediada por células T CD8+. En conjunto, estos resultados ponen de relieve el potencial de LNP H como nueva estrategia para mejorar la inmunogenicidad tumoral y provocar fuertes respuestas inmunitarias antitumorales., [EN] This doctoral thesis, entitled "Remodeling the Tumor Immune Microenvironment with Lipid Nanoparticles", explores the development of novel cancer immunotherapeutic strategies at both the therapeutic and delivery levels. Specifically, the work investigates alternative and comparatively underexplored approaches, including macrophage-based immunotherapies and exogenous antigen-mediated immunotherapy, which seek to overcome key limitations of current immunotherapeutic modalities. In parallel, the thesis evaluates lipid nanoparticles (LNPs) as non-viral gene delivery systems for immunotherapy. The first experimental chapter describes the development of a novel LNP platform for macrophage-based immunotherapy. LNPs loaded with either luciferase-encoding plasmid DNA or mRNA were functionalized with folic acid (FA) for targeting folate receptor-expressing pancreatic cancer cells and with an anti-CD47 antibody (aCD47) to block CD47-mediated immune evasion. The results demonstrate efficient transfection of pancreatic cancer cells, with mRNA-loaded LNPs outperforming plasmid-based formulations. Moreover, the functionalization with FA enhanced targeted uptake of LNPs in vitro and aCD47 functionalization restored the phagocytosis of tumor cells by macrophages in vitro. In vivo experiments in mouse Capan-2 xenograft models with LNP-mRNA-FA-aCD47 demonstrated in vivo expression of luciferase and promoted a shift to a pro-inflammatory, M1-like macrophage phenotype within the tumor microenvironment. Together, these results present an optimized LNP platform capable of immunomodulating tumor-associated macrophages. The second experimental chapter presents a novel exogenous antigen-mediated immunotherapy based on the alpha-Gal epitope (galactose-alpha-1,3-galactose). alpha-Gal epitope is highly immunogenic in humans and elicits strong pre-existing antibody responses. LNPs encoding alpha-1,3-galactosyltransferase (alpha-GT) mRNA were developed to enable endogenous alpha-Gal biosynthesis on tumor cell surfaces. Treatment with these LNPs successfully induced alpha-Gal expression in both murine and human cancer cell lines and promoted the recruitment of naturally occurring human anti-alpha-Gal antibodies to tumor cells. These results identify LNP alpha as a promising immunotherapeutic platform that exploits pre-existing humoral immunity. The third experimental chapter describes a novel exogenous antigen-mediated immunotherapy based on the hemagglutinin (H) protein of the measles virus. H protein is a highly immunogenic antigen in humans due to widespread vaccination against measles virus. LNPs encoding H protein were formulated and shown to efficiently transfect both two-dimensional cancer cell cultures and three-dimensional tumor spheroids. Moreover, in vivo administration of H-expressing LNPs in measles-vaccinated mice bearing B16-BL6 melanoma tumors resulted in significant tumor growth delay. This therapeutic effect is associated with robust intratumoral infiltration of CD8+ cytotoxic T lymphocytes, a shift in the CD8/CD4 T cell ratio, and ex vivo production of pro-inflammatory cytokines upon antigen recall, hallmarks of a potent CD8+ T cell-mediated immune response. Together, these results highlight the potential of LNP H as a novel strategy to enhance tumor immunogenicity and elicit strong antitumor immune responses. We hope that the results obtained in this doctoral thesis will demonstrate the versatility of LNP-based platforms and support the development of innovative cancer immunotherapies that leverage alternative immunotherapeutic strategies, such as macrophage-based approaches and exogenous antigen-mediated immunotherapy., [CA] Esta tesi doctoral, titulada «Remodelació del microambient immunitari tumoral amb nanopartícules lipídiques», explora el desenvolupament de noves estratègies immunoterapèutiques contra el càncer, tant a nivell terapèutic com de mètodes d'administració. En concret, el treball investiga enfocaments alternatius i relativament poc explorats, com les immunoteràpies basades en macròfags i la immunoteràpia mediada per antígens exògens, que tracten de superar les principals limitacions de les modalitats immunoterapèutiques actuals. Paral·lelament, la tesi avalua les nanopartícules lipídiques (LNP) com a sistemes d'administració de gens no virals per a la immunoteràpia. El primer capítol experimental descriu el desenvolupament d'una nova plataforma LNP per a la immunoteràpia basada en macròfags. Les LNP carregades amb ADN plasmídic o ARNm de luciferasa es van funcionalitzar amb àcid fòlic (FA) per a dirigir-se a les cèl·lules canceroses pancreàtiques que expressen el receptor de folat i amb un anticòs anti-CD47 (aCD47) per a bloquejar l'evasió immunitària mediada per CD47. Els resultats demostren una transfecció eficaç de les cèl·lules de càncer de pàncrees, amb les LNP carregades amb ARNm superant a les formulacions basades en plasmidis. A més, la funcionalització amb FA va millorar la captació dirigida de LNP in vitro i la funcionalització amb aCD47 va restaurar la fagocitosi de les cèl·lules tumorals pels macròfags in vitro. Els experiments in vivo en models de xenotrasplantament Capan-2 de ratolí amb LNP-ARNm-FA-aCD47 van demostrar l'expressió in vivo de luciferasa i van promoure un canvi cap a un fenotip de macròfags proinflamatori M1 dins del microambient tumoral. En conjunt, aquests resultats presenten una plataforma LNP optimitzada, capaç de immunomodular els macròfags associats a tumors. El segon capítol experimental presenta una nova immunoteràpia mediada per antígens exògens basada en el epítop alpha-Gal (galactosa-¿-1,3-galactosa). El epítop alpha-Gal és altament immunogènic en humans i provoca fortes respostes a causa d'anticossos preexistents. Es van desenvolupar LNP que codifiquen el ARNm de la ¿-1,3-galactosiltransferasa (¿-GT) per a permetre la biosíntesi endògena de ¿-Gal en la superfície de les cèl·lules tumorals. El tractament amb estes LNP va induir amb èxit l'expressió de ¿-Gal en línies cel·lulars canceroses murines i humanes i va promoure el reclutament d'anticossos anti-¿-Gal humans naturals cap a les cèl·lules tumorals. Estos resultats identifiquen a la LNP alpha com una plataforma immunoterapèutica prometedora que aprofita la immunitat humoral preexistent. El tercer capítol experimental descriu una nova immunoteràpia mediada per antígens exògens basada en la proteïna hemaglutinina (H) del virus de la xarampió. La proteïna H és un antigen altament immunogènic en humans a causa de la vacunació generalitzada contra el virus de la pallola. Es van formular LNP que codifiquen la proteïna H i es va demostrar que transfecten eficaçment tant cultius cel·lulars cancerosos bidimensionals com esferoides tumorals tridimensionals. A més, l'administració in vivo de LNP H en ratolins vacunats contra la pallola amb tumors de melanoma B16-BL6 va donar lloc a una disminució significativa del creixement tumoral. Aquest efecte terapèutic està associat amb una forta infiltració intratumoral de limfòcits T citotòxics CD8+, un canvi en la proporció de cèl·lules T CD8/CD4 i la producció ex vivo de citocines proinflamatòries després de la reactivació de l'antigen, característiques distintives d'una potent resposta immunitària mediada per cèl·lules T CD8+. En conjunt, aquests resultats posen en relleu el potencial de LNP H com a nova estratègia per millorar la immunogenicitat tumoral i provocar fortes respostes immunitàries antitumorals. Esperem que els resultats obtinguts en aquesta tesi doctoral demostren la versatilitat de les plataformes basades en LNP i recolzen el desenvolupament d'immunoteràpies innovadores contra el càncer., This research was supported by European Union’s Horizon 2020 research and innovation programme under grant agreement No 899708 (ULISES). The work has also received funding from projects PID2020-119692RB-C22, PID2023-146637OB-C22, PID2021-128141OBC22, PID2021-126304OB-C41 and PID2024-155683OB-C41 funded by MCIN-Ministerio de Ciencia e Innovación and by the European Regional Development Fund—A way of doing Europe. This study was also supported by the ERC Advanced Grant Edison (101052997), the Generalitat Valenciana (CIPROM/2021/007) and CIBER (CB06/01/2012) and (RD21/0017/0012) Instituto de Salud Carlos III, the Generalitat de Catalunya (SGR21/01169). The research leading to these results has also received funding from “la Caixa” Foundation under agreement LCF/PR/SP23/52950009. The Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Research Council. Neither the European Union nor the granting authority can be held responsible for them. J.M-L. is grateful to the Spanish MECD for his FPU grant (FPU19/06219). PM.S-T. is grateful to the Generalitat Valenciana for a postdoctoral Investigo contract (INVEST/2023/443). We also acknowledge the support of CERCA Programme/Generalitat de Catalunya.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Noninvasive assessment of the ventricular arrhythmogenic substrate using electrocardiographic imaging during sinus rhythm: The NIAVAS study

  • Reventós-Presmanes, Jana
  • Hernández-Romero, Ismael
  • Pecllier-Sendra, B.
  • Guillen-Buisan, E.
  • Serrano-Campaner, J.
  • Invers-Rubio, E.
  • Regany-Closa, M.
  • Garre, Paz
  • Borras, Roger
  • Costafreda, Adriana
  • Arbelo, Elena
  • Tolosana, Jose M.
  • Guasch, E.
  • Althoff, Till F.
  • Guichard, Jean-Baptiste
  • Falzone, Pasquale V.
  • Vázquez-Calvo, Sara
  • Elivhots Ayauja
  • Porta-Sanchez, Andreu
  • Roca-Luque, Ivo
  • Guillem Sánchez, María Salud|||0000-0001-5660-3693
  • Andreu M. Climent|||0000-0002-7260-8811
[EN] Background Late gadolinium enhancement cardiac magnetic resonance (LGE-CMR) identifies structural properties associated with ventricular tachycardia (VT) but lacks functional information. Noninvasive identification of slow conduction regions using electrocardiographic imaging (ECGI) could complement LGE-CMR to aid VT risk stratification. Objective This study aimed to evaluate the relationship between ventricular arrhythmogenic substrate and regional ECGI markers during sinus rhythm in patients with ischemic cardiomyopathy (ICM). Methods Seventy-two patients were included: 29 with ICM evidenced by LGE-CMR referred for VT ablation, 17 with ICM with implantable cardioverter-defibrillator for primary prevention without documented VT, and 26 controls. ECGI-derived regional activation dispersion (rAD) and pseudo-regional conduction velocity (pseudo-rCV) were analyzed and compared between scarred and healthy regions based on LGE, and between patients with ICM with and without previous VT. In a subgroup with electroanatomic mapping (n = 16), deceleration zones were correlated with ECGI. Results Scarred regions showed higher rAD (46.3 ± 2.2 vs 30.1 ± 1.7 ms, P < .001) and reduced pseudo-rCV (149.9 ± 3.0 vs 165.7 ± 2.4 cm/s, P < .001) than healthy regions. In the subgroup with sinus rhythm electroanatomic mapping, regions containing deceleration zones showed increased rAD (64.9 ± 5.4 vs 43.1 ± 3.1 ms, P < .001), and ECGI identified 70.4% of those zones. At the patient level, the mean of the 3 regions with the highest activation dispersion differentiated patients with ICM with and without previous VT (rAD ¿60.0 ms, sensitivity 75.9%, area under the curve [AUC] 0.75, P = .005) and identified patients with ICM from controls (rAD ¿39.5 ms, AUC 0.93). Conclusion This study introduces a novel regional ECGI methodology demonstrating that rAD identifies abnormalities linked to arrhythmogenic substrate and could help identify patients at risk of VT. These findings highlight ECGI¿s potential as a complementary tool to LGE-CMR., This research was funded by the European Institute of Innovation and Technology (EIT Health) under grant agreement no. 230129. In addition, the research was supported by Ministerio de Ciencia, Innovación y Universidades MCIN/AEI/10.13039/501100011033 (grant PID2023-149812OB-I00), European Union NextGenerationEU/Plan de Recuperación, Transformación y Resiliencia (CNS2022-135512, PTQ2023-013018, and CPP2021- 008562), and Fondo Europeo de Desarrollo Regional European Union (CPP2023-010504). Additional support came from Generalitat Valenciana and European Social Fund Investing in Your Future (grants CIAPOS/2021/238 and CIAICO/2022/020), Instituto de Salud Carlos III (grant CIBERCV16 CB16/11/00354), and Catalonia, Spain (grants 2021_SGR_01350 and SGR21/GENCAT).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Substrate Mapping for Ventricular Tachycardia Ablation Through High-Density Whole-Chamber Double Extra Stimuli The S3 Protocol

  • Guichard, Jean Baptiste
  • Regany-Closa, Mariona
  • Vázquez-Calvo, Sara
  • Zazu, Blanca
  • Pellicer Sendra, Berta
  • Serrano-Campaner, Jaume
  • Molero-Pereira, Silvia
  • Borras, Roger
  • Ortiz, Jose Tomas
  • Falzone, Pasquale Valerio
  • Eulogio, Frida
  • Reventós-Presmanes, Jana
  • Garre, Paz
  • Arbelo, Elena
  • Althoff, Till Friedrisch
  • Eduard Guasch
[EN] Background: A partial delineation of targets for ablation of ventricular tachycardia (VT) during a stable rhythm is likely responsible for a suboptimal success rate. The abnormal low-voltage near-field functional components may be hidden within the high-amplitude far-field signal. Objectives: The aim of this study was to evaluate the benefit and feasibility of functional substrate mapping using a full-ventricle S3 protocol and to assess its colocalization with arrhythmogenic conducting channels (CCs) on late gadolinium enhancement cardiac magnetic resonance. Methods: An S3 mapping protocol with a drive train of S1 followed by S2 (effective refractory period + 30 ms) and S3 (effective refractory period + 50 ms) from the right ventricular apex was performed in 40 consecutive patients undergoing scar-related VT ablation. Deceleration zones (DZs) and areas of late potentials (LPs) were identified for all maps. A preprocedural noninvasive substrate assessment was done using late gadolinium enhancement cardiac magnetic resonance and postprocessing with automated CC identification. Results: The S3 protocol was completed in 34 of the 40 procedures (85.0%). The S3 protocol enhanced the identification of VT isthmus on the basis of DZ (89% vs 62%; P < 0.01) and LP (93% vs 78%; P = 0.04) assessment. The percentage of CCs unmasked by DZs and LPs using S3 maps was significantly higher than the ones using S2 and S1 maps (78%, 65%, and 48% [P < 0.001] and 88%, 81%, and 68% [P < 0.01], respectively). The functional substrate identified during S3 activation mapping was significantly more extensive than the one identified using S2 and S1, including a greater number of DZs (2.94, 2.47, and 1.82, respectively; P < 0.001) and a wider area of LPs (44.1, 38.2, and 29.4 cm(2), respectively; P < 0.001). After VT ablation, 77.9% of patients have been VT free during a median follow-up period of 13.6 months. Conclusions: The S3 protocol was feasible in 85% of patients, allows a better identification of targets for ablation, and might improve VT ablation results., Dr Guichard has received institutional grant support from the French Federation of Cardiology and from "Contractes d'Investigacio Avan-cada Fundacio BBVA-Hospital Clinic Barcelona Joan Rodes - Josep Baselga 2022" (HCB_BIO_001/2) . This study was supported in part by grant PI20/00693, FEDER (European Commission) /CB16/11/00354, Instituto de Salud Carlos III, and grant 2021_SGR_01350, SGR21/GEN-CAT.
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Position-specific polymeric-coated oncolytic adenovirus improves anti-tumor efficacy and evades neutralizing antibodies in pancreatic cancer models

  • Otero, Marc
  • Estrany Castillo, Francesc
  • Pembaur, Daniel
  • Gracia Batllori, Albert
  • Parés, Marta
  • Díaz Permanyer, Adrià
  • Brugada-Vilà, Pau
  • Fornaguera, Cristina
  • Cascante, Anna
  • Borrós, Salvador
  • Kreppel, Florian
  • Fillat, Cristina
Enhancing the safety and efficacy of systemically administered oncolytic adenoviruses remains a significant challenge to achieve effective targeting of primary tumors and disseminated disease. Intravenous administration exposes viral particles to various blood components interfering with their therapeutic activity. To protect adenoviruses from the inactivating factors we developed a shielding strategy based on a nanoparticle formulation reactive to a specific-site in the hexon hypervariable region 1. We propose a novel coating approach based on the combination of a bioresponsive oligopeptide-modified poly(β-aminoester)s (OM-PBAE-CRRR) and an irreversible linear PEG polymer with protruding ends to shield the oncolytic adenovirus AdNuPARc-E (PEPB). The formulated virus displays a slight delay in the transduction and replicative capacity at early time points that normalizes in a few days. Interestingly, similar oncolytic efficacy to the naked virus was observed in vitro, with enhanced antitumor effect in vivo in a pancreatic cancer model. In accordance, PEPB showed significantly enhanced pharmacokinetics and increased liver and tumor transduction in the xenograft model. In the presence of neutralizing antibodies (NAbs) coated viral particles maintained the infectivity and the replication capacity. Notably, in pre-immunized immunocompetent mice, protection from NAbs resulted in a higher viral accumulation in tumors than in the liver and was associated with significant antitumor activity. In summary, our findings indicate that the proposed formulation PEPB —the oncolytic adenovirus AdNuPARc-E site-specifically shielded with OM-PBAE-CRRR/PEG — offers a promising approach to improve tumor targeting after systemic administration, even in the presence of pre-existing neutralizing antibodies., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Assessing neurological and cardiovascular effects caused by pharmaceuticals in river water: Insights from Daphnia magna and Danio rerio embryos

  • Romero Alfano, Irene
  • Prats, Eva
  • Raldua, Demetrio
  • Blazquez, Mercedes
  • Tauler, Roma
  • Piña, Benjamí
  • Gómez-Canela, Cristian
  • Barata, Carlos
Pharmaceutical residues in surface waters are an emerging environmental and public health issue, yet their biological impacts on aquatic life remain poorly understood. This study presents a cost-effective bioanalytical framework using Daphnia magna juveniles and zebrafish (Danio rerio) embryos to evaluate neurotoxic and cardiotoxic effects of pharmaceutical mixtures in rivers downstream of wastewater treatment plant (WWTP) effluents. Water samples from three rivers in north-eastern Spain (Besòs, Llobregat, and Onyar) were concentrated up to 5- and 20-fold using solid-phase extraction. Bioassays were conducted over 24 h for D. magna and five days for zebrafish embryos. Eighty pharmaceutical compounds were quantified via HPLC-MS and linked with phenotypic endpoints including locomotion, feeding, heart rate, neurotransmitter profiles, and metabolomic alterations. Of the 28 concentrated extracts, four were acutely toxic to zebrafish embryos. Altered behavioral and cardiovascular responses were observed in 22.2 % (D. magna) and 35.1 % (D. rerio) of extracts, primarily at higher enrichment. Concentrations of 31 pharmaceuticals were statistically associated with observed effects. Neuroactive drugs such as topiramate, rasagiline, citalopram, and fluvoxamine showed strong correlations with altered neurotransmitter levels in zebrafish, consistent with their known mechanisms. Seven additional compounds with secondary neuroactive properties were linked to similar neurological disruptions. Seventeen pharmaceuticals were associated with disturbances in amino acid metabolism and urea cycle pathways, indicating broader metabolic dysregulation. Overall, nearly 75 % of river extracts showed no observable effect, but several samples were acutely toxic or induced sublethal neurobehavioral and metabolic responses. These findings support the utility of D. magna and zebrafish (D. rerio) embryos as sensitive and complementary biosentinels for monitoring pharmaceutical pollution and highlight zebrafish as a relevant model for studying environmentally driven neurotoxicity with potential human health implications., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Assessing neurological and cardiovascular effects caused by pharmaceuticals in river water: Insights from Daphnia magna and Danio rerio embryos

  • Romero Alfano, Irene
  • Prats, Eva
  • Raldua, Demetrio
  • Blazquez, Mercedes
  • Tauler, Roma
  • Piña, Benjamí
  • Gómez-Canela, Cristian
  • Barata, Carlos
Pharmaceutical residues in surface waters are an emerging environmental and public health issue, yet their biological impacts on aquatic life remain poorly understood. This study presents a cost-effective bioanalytical framework using Daphnia magna juveniles and zebrafish (Danio rerio) embryos to evaluate neurotoxic and cardiotoxic effects of pharmaceutical mixtures in rivers downstream of wastewater treatment plant (WWTP) effluents. Water samples from three rivers in north-eastern Spain (Besòs, Llobregat, and Onyar) were concentrated up to 5- and 20-fold using solid-phase extraction. Bioassays were conducted over 24 h for D. magna and five days for zebrafish embryos. Eighty pharmaceutical compounds were quantified via HPLC-MS and linked with phenotypic endpoints including locomotion, feeding, heart rate, neurotransmitter profiles, and metabolomic alterations. Of the 28 concentrated extracts, four were acutely toxic to zebrafish embryos. Altered behavioral and cardiovascular responses were observed in 22.2 % (D. magna) and 35.1 % (D. rerio) of extracts, primarily at higher enrichment. Concentrations of 31 pharmaceuticals were statistically associated with observed effects. Neuroactive drugs such as topiramate, rasagiline, citalopram, and fluvoxamine showed strong correlations with altered neurotransmitter levels in zebrafish, consistent with their known mechanisms. Seven additional compounds with secondary neuroactive properties were linked to similar neurological disruptions. Seventeen pharmaceuticals were associated with disturbances in amino acid metabolism and urea cycle pathways, indicating broader metabolic dysregulation. Overall, nearly 75 % of river extracts showed no observable effect, but several samples were acutely toxic or induced sublethal neurobehavioral and metabolic responses. These findings support the utility of D. magna and zebrafish (D. rerio) embryos as sensitive and complementary biosentinels for monitoring pharmaceutical pollution and highlight zebrafish as a relevant model for studying environmentally driven neurotoxicity with potential human health implications., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Position-specific polymeric-coated oncolytic adenovirus improves anti-tumor efficacy and evades neutralizing antibodies in pancreatic cancer models

  • Otero, Marc
  • Estrany Castillo, Francesc
  • Pembaur, Daniel
  • Gracia Batllori, Albert
  • Parés, Marta
  • Díaz Permanyer, Adrià
  • Brugada-Vilà, Pau
  • Fornaguera, Cristina
  • Cascante, Anna
  • Borrós, Salvador
  • Kreppel, Florian
  • Fillat, Cristina
Enhancing the safety and efficacy of systemically administered oncolytic adenoviruses remains a significant challenge to achieve effective targeting of primary tumors and disseminated disease. Intravenous administration exposes viral particles to various blood components interfering with their therapeutic activity. To protect adenoviruses from the inactivating factors we developed a shielding strategy based on a nanoparticle formulation reactive to a specific-site in the hexon hypervariable region 1. We propose a novel coating approach based on the combination of a bioresponsive oligopeptide-modified poly(β-aminoester)s (OM-PBAE-CRRR) and an irreversible linear PEG polymer with protruding ends to shield the oncolytic adenovirus AdNuPARc-E (PEPB). The formulated virus displays a slight delay in the transduction and replicative capacity at early time points that normalizes in a few days. Interestingly, similar oncolytic efficacy to the naked virus was observed in vitro, with enhanced antitumor effect in vivo in a pancreatic cancer model. In accordance, PEPB showed significantly enhanced pharmacokinetics and increased liver and tumor transduction in the xenograft model. In the presence of neutralizing antibodies (NAbs) coated viral particles maintained the infectivity and the replication capacity. Notably, in pre-immunized immunocompetent mice, protection from NAbs resulted in a higher viral accumulation in tumors than in the liver and was associated with significant antitumor activity. In summary, our findings indicate that the proposed formulation PEPB —the oncolytic adenovirus AdNuPARc-E site-specifically shielded with OM-PBAE-CRRR/PEG — offers a promising approach to improve tumor targeting after systemic administration, even in the presence of pre-existing neutralizing antibodies., info:eu-repo/semantics/publishedVersion
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Quantitative analysis of somatically acquired and constitutive uniparental disomy in gastrointestinal cancers

  • Torabi Asensio, Keyvan|||0000-0002-9067-0061
  • Erola, Pau
  • Álvarez Mora, María Isabel|||0000-0003-3788-8915
  • Díaz-Gay, Marcos|||0000-0003-0658-0467
  • Ferrer Menduiña, Queralt|||0000-0003-3177-4618
  • Castells, Antoni|||0000-0001-8431-2033
  • Castellví-Bel, Sergi|||0000-0003-1217-5097
  • Milà, Montserrat
  • Lozano, Juan José
  • Miró Ametller, Rosa|||0000-0003-2508-5074
  • Ried, Thomas|||0000-0002-0767-6009
  • Ponsa Arjona, Immaculada|||0000-0003-3436-1907
  • Camps Polo, Jordi|||0000-0003-2929-4228
Somatically acquired uniparental disomies (aUPDs) are frequent events in solid tumors and have been associated with cancer-related genes. Studies assessing their functional consequences across several cancer types are therefore necessary. Here, we aimed at integrating aUPD profiles with the mutational status of cancer-related genes in a tumor-type specific manner. Using TCGA datasets for 1,032 gastrointestinal cancers, including colon (COAD), rectum (READ), stomach (STAD), esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESCC), we show a non-random distribution of aUPD, suggesting the existence of a cancer-specific landscape of aUPD events. Our analysis indicates that aUPD acts as a "second hit" in Knudson's model in order to achieve biallelic inactivation of tumor suppressor genes. In particular, APC , ARID1A and NOTCH1 were recurrently inactivated by the presence of homozygous mutation as a consequence of aUPD in COAD and READ, STAD and ESCC, respectively. Furthermore, while TP53 showed inactivation caused by aUPD at chromosome arm 17p across all tumor types, copy number losses at this genomic position were also frequent. By experimental and computationally inferring genome ploidy, we demonstrate that an increased number of aUPD events, both affecting the whole chromosome or segments of it, were present in highly aneuploid genomes compared to near-diploid tumors. Finally, the presence of mosaic UPD was detected at a higher frequency in DNA extracted from peripheral blood lymphocytes of patients with colorectal cancer compared to healthy individuals. In summary, our study defines specific profiles of aUPD in gastrointestinal cancers and provides unequivocal evidence of their relevance in cancer.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

CNApp, a tool for the quantification of copy number alterations and integrative analysis revealing clinical implications

  • Franch-Expósito, Sebastià|||0000-0002-4542-1701
  • Bassaganyas, Laia|||0000-0002-4575-0214
  • Vila-Casadesús, Maria|||0000-0001-6597-7953
  • Hernández-Illán, Eva
  • Esteban-Fabró, Roger
  • Díaz-Gay, Marcos|||0000-0003-0658-0467
  • Lozano, Juan José
  • Castells, Antoni|||0000-0001-8431-2033
  • Llovet, Josep Maria
  • Castellví-Bel, Sergi|||0000-0003-1217-5097
  • Camps Polo, Jordi|||0000-0003-2929-4228
Somatic copy number alterations (CNAs) are a hallmark of cancer, but their role in tumorigenesis and clinical relevance remain largely unclear. Here, we developed CNApp, a web-based tool that allows a comprehensive exploration of CNAs by using purity-corrected segmented data from multiple genomic platforms. CNApp generates genome-wide profiles, computes CNA scores for broad, focal and global CNA burdens, and uses machine learning-based predictions to classify samples. We applied CNApp to the TCGA pan-cancer dataset of 10,635 genomes showing that CNAs classify cancer types according to their tissue-of-origin, and that each cancer type shows specific ranges of broad and focal CNA scores. Moreover, CNApp reproduces recurrent CNAs in hepatocellular carcinoma and predicts colon cancer molecular subtypes and microsatellite instability based on broad CNA scores and discrete genomic imbalances. In summary, CNApp facilitates CNA-driven research by providing a unique framework to identify relevant clinical implications. CNApp is hosted at . In most cases, human cells contain two copies of each of their genes, yet sometimes this can change, an effect called copy number alteration (CNA). Cancer is a genetic disease and thus, studying the DNA from tumor samples is crucial to improving diagnosis and choosing the right treatment. Most tumors contain cells with CNAs; however, the impact of CNAs in cancer progression is poorly understood. CNAs can be studied by examining the genome of tumor cells and finding which regions display an unusual number of copies. It may also be possible to gather information about different cancer types by analyzing the CNAs in a tumor, but this approach requires the analysis of large amounts of data. To aid the analysis of CNAs in cancer cells, Franch-Expósito, Bassaganyas et al. have created an online tool called CNApp, which is able to identify and count CNAs in genomic data and link them to features associated with different cancers. The hope is that a better understanding of the effect of CNAs in cancer could help better diagnose cancers, and improve outcomes for patients. Potentially, this could also predict what type of treatment would work better for a specific tumor. Besides, by using a machine-learning approach, the tool can also make predictions about specific cancer subtypes in order to facilitate clinical decisions. Franch-Expósito, Bassaganyas et al. tested CNApp using previously existing cancer data from 33 different cancer types to show how CNApp can help the interpretation of CNAs in cancer. Moreover, CNApp can also use CNAs to identify different types of bowel (colorectal) cancer in a way that could help doctors to make decisions about treatment. Together these findings show that CNApp provides an adaptable and accessible research tool for the study of cancer genomics, which could provide opportunities to inform medical procedures.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Exome sequencing of early-onset patients supports genetic heterogeneity in colorectal cancer

  • Fernández-Rozadilla, Ceres|||0000-0001-7330-4804
  • Álvarez-Barona, Miriam|||0000-0002-3843-7481
  • Quintana, Isabel
  • López-Novo, Jorge Amigo
  • Amigo, Jorge|||0000-0002-1362-2605
  • Cameselle-Teijeiro, José Manuel|||0000-0002-5516-8914
  • Roman, Eva|||0000-0001-9084-8555
  • Gonzalez, Dolors
  • Llor, Xavier|||0000-0002-6259-185X
  • Bujanda, Luis|||0000-0002-4353-9968
  • Bessa Caserras, Xavier|||0000-0003-4680-1228
  • Jover, Rodrigo
  • Balaguer, Francesc|||0000-0002-0206-0539
  • Castells, Antoni|||0000-0001-8431-2033
  • Castellví-Bel, Sergi|||0000-0003-1217-5097
  • Capella, Gabriel|||0000-0002-4669-7320
  • Carracedo, Ángel|||0000-0003-1085-8986
  • Valle, Laura|||0000-0003-0371-0844
  • Ruiz-Ponte, Clara|||0000-0002-2200-0162
Colorectal cancer (CRC) is a complex disease that can be caused by a spectrum of genetic variants ranging from low to high penetrance changes, that interact with the environment to determine which individuals will develop the disease. In this study, we sequenced 20 early-onset CRC patients to discover novel genetic variants that could be linked to the prompt disease development. Eight genes, CHAD, CHD1L, ERCC6, IGTB7, PTPN13, SPATA20, TDG and TGS1, were selected and re-sequenced in a further 304 early onset CRC patients to search for rare, high-impact variants. Although we found a recurring truncating variant in the TDG gene shared by two independent patients, the results obtained did not help consolidate any of the candidates as promising CRC predisposing genes. However, we found that potential risk alleles in our extended list of candidate variants have a tendency to appear at higher numbers in younger cases. This supports the idea that CRC onset may be oligogenic in nature and may show molecular heterogeneity. Further, larger and robust studies are thus needed to unravel the genetics behind early-onset CRC development, coupled with novel functional analyses and omic approaches that may offer complementary insight.